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Abstract
Normal and malignant cells release a variety of different vesicles into their extracellular environment. The most
prominent vesicles are the microvesicles (MVs, 100-1 000 nm in diameter), which are shed of the plasma membrane,
and the exosomes (70-120 nm in diameter), derivates of the endosomal system. MVs have been associated with
intercellular communication processes and transport numerous proteins, lipids and RNAs. As essential component of
immune-escape mechanisms tumor-derived MVs suppress immune responses. Additionally, tumor-derived MVs
have been found to promote metastasis, tumor-stroma interactions and angiogenesis. Since members of the
carcinoembryonic antigen related cell adhesion molecule (CEACAM)-family have been associated with similar
processes, we studied the distribution and function of CEACAMs in MV fractions of different human epithelial tumor
cells and of human and murine endothelial cells. Here we demonstrate that in association to their cell surface
phenotype, MVs released from different human epithelial tumor cells contain CEACAM1, CEACAM5 and CEACAM6,
while human and murine endothelial cells were positive for CEACAM1 only. Furthermore, MVs derived from
CEACAM1 transfected CHO cells carried CEACAM1. In terms of their secretion kinetics, we show that MVs are
permanently released in low doses, which are extensively increased upon cellular starvation stress. Although
CEACAM1 did not transmit signals into MVs it served as ligand for CEACAM expressing cell types. We gained
evidence that CEACAM1-positive MVs significantly increase the CD3 and CD3/CD28-induced T-cell proliferation. All
together, our data demonstrate that MV-bound forms of CEACAMs play important roles in intercellular
communication processes, which can modulate immune response, tumor progression, metastasis and angiogenesis.
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Introduction
A broad range of cell types including epithelial and
endothelial cells, leukocytes and tumor cells are able to release
at least three major types of extracellular vesicles. Vesicles
derived from the endosomal system are termed exosomes and
have a diameter of 70-120 nm [1,2]. Per definition exosomes
originate from late endosomes, which upon their maturation
bud small vesicles, the intraluminal vesicles, into their interior.
Accordingly such endosomes are also termed multivesicular
bodies (MVBs). Upon fusion of the outer membranes of the
MVB with the plasma membrane they can release their
intraluminal vesicles as exosomes into their environment [3].
Exosomes can be released constitutively or upon induction [4].
With 100-1 000 nm in diameter microvesicles (MVs) are
larger in size than exosomes [4]. MVs are shed from the cell
membrane. MV shedding is a physiological phenomenon that
accompanies cell activation and growth. Their secretion can be
increased by stress factors such as cell activation, hypoxia,
lack of nutrition, irradiation, oxidative injury, and subsequent
increase of cytosolic Ca2+ [5,6]. Released microvesicles have
been isolated and characterized from cultured cell lines as well
as from various body fluids including blood plasma, serum,
urine, amniotic fluid, bronchoalveolar fluid, and tumor effusion
[4,5]. Increased levels of MVs have been detected in peripheral
blood of patients suffering from tumors with highly metastatic
potential [7–9]. A third class of cell-derived microvesicles is the
apoptotic bodies, which are released as blebs of cells
undergoing the programmed cell death. In contrast to the other
types of vesicles apoptotic bodies are considerably larger at ~
1-5 µm in diameter and contain DNA fragments and organelles,
like mitochondria, lysosomes and ribosomes [10–12].
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In this study we focused on analyzing MVs. MVs play an
important role in modulating numerous cellular processes, such
as angiogenesis, tumor progression and metastasis, cancer
immune suppression, tumor-stroma interactions, and further
biological processes [13]. Analogous physiological and
pathological functions have been shown for members of the
carcinoembryonic antigen (CEA)-related cell adhesion
molecule (CEACAM) family.
CEACAMs belong to the immunoglobulin (Ig) superfamily
and thus appear as highly glycosylated proteins with the typical
N-terminal variable Ig-like domain followed by 0 to 6 constant
Ig-like domains [14,15]. A hydrophobic transmembrane domain
with a cytoplasmic tail (CEACAM1-CEACAM4) or a
glycosylphosphatidylinositol (GPI) lipid moiety (CEACAM5-
CEACAM8) anchors CEACAMs to the cell membrane
[14,16,17]. The transmembrane bound CEACAMs can mediate
signal transduction utilizing their cytoplasmic phospho-tyrosine
based signaling motifs (ITIM in CEACAM1, ITAM in
CEACAM3) [18–21]. CEACAMs function as low affinity
homophilic and heterophilic cell-cell adhesion receptors that
often act as co-receptors e.g. of the T-cell receptor [22], B-cell
receptor [23], TLR-2 [24], TLR4 [25], VEGFR1 [26,27],
VEGFR2 [28], VEGFR3 [29], EGFR [30], insulin receptor
[31,32] and the GM-CSFR [33]. CEACAMs can be found in
epithelia, angiogenically activated endothelia, and most
leukocyte subtypes [20,34,35], although the CEACAM
expression pattern varies significantly between these cell
types. In human, epithelia express CEACAM1, CEACAM5,
CEACAM6 and CEACAM7, while granulocytes express
CEACAM1, CEACAM3, CEACAM6 and CEACAM8. In
contrast, lymphocytes and activated endothelial cells only
express CEACAM1 [16,26,36,37]. The CEACAM expression in
other species is mostly restricted to CEACAM1 [36]. Therefore
CEACAM1 is regarded as the ancestral founder molecule of
the CEACAM family [36].
So far no data exist on the presence and functions of
CEACAMs on MVs. Therefore we investigated the CEACAM
expression pattern on tumor and endothelial cell-derived MVs
of different species. Furthermore we analyzed the signaling
properties of CEACAM1 in MVs and the function of tumor
derived CEACAM positive MVs on T-lymphocytes. We found
that CEACAM1, CEACAM5 and CEACAM6 are present on
tumor-derived MVs, and that human and murine endothelial
cells release CEACAM1 expressing MVs. Pervanadate
treatment of MVs did not provoke tyrosine phosphorylation of
CEACAM1 suggesting a lack of its signal transduction
capability. However, CEACAM-positive MVs increased the
proliferative response of T-cells stimulated by CD3/CD28.
Results
Morphological examination of MVs
MVs are released from luminal cell surface membranes
when protrusions bleb off. In order to observe this process,
HT29 cells were cultured on a Thermanox coverslip for 3 days,
and prepared for electron microscopy, as described in
Materials and Methods. Transmission electron microscopy
showed chubby protrusions of luminal cell membranes with
electro-lucent content and little texture indicating a high
percentage of water. Eventually, a few spherical vesicles with
similar light content were present in the media, i.e. MVs. Our
results showed no significant budding off of MVs in control cells
cultured with FCS containing medium (Figure 1A, panel a).
Cells cultured in FCS free medium revealed circular structures
located closely to, or protruding from, the outer cell membrane
(Figure 1A, arrows panel b). Note the two distinct sites where
protrusions with mainly electron lucent, i.e. water-rich, content
appear. These are a direct continuation of the much more
electron-dense cytoplasm that kind of surrounds the watery
region (Figure 1A panel b, arrows). We concluded that these
circular structures are MVs released from the cell membrane.
Following this idea we collected the same volume of cell culture
supernatants of starved and non-starved HT29 cells and
determined the amount of MVs counted by a flow cytometer
within one minute (counts per minute, c/m). As shown in Figure
1B control cells showed barely any MVs in the supernatant
(350 ± 70 c/m, n=3) whereas starved cells release significant
amounts of MVs (7530 ± 1200 c/m, n = 3). These results
clearly show that starving cells induced the release of MVs.
Next we developed a method to isolate MVs without potential
contamination with apoptotic bodies. The common procedure
for the isolation of MVs from cell culture supernatants involves
differential centrifugation [38]. Unfortunately probes isolated by
this technique are known to be contaminated by microsomal
fractions and organelles released from apoptotic cells. To avoid
such contaminations in the MVs isolates, we introduced a
special filtration step into our MVs isolation method. To show
the benefit of this filtration step we collected the supernatant of
HT29 cells cultured for 3 days in starvation medium. After
centrifugation at 2860 g for 20 minutes at 4°C the sample was
divided in two fractions. One supernatant fraction was filtered
through a 0.8 µm sterile filter whereas the other was left
untreated. Thereafter both supernatant fractions were
centrifuged at 41 000 g for 1 hour at 4°C. Then the pellet was
prepared for electron microscopy. Analyzes of the ultrathin
sections demonstrated that MVs harvested from the fraction
without filtration were contaminated with considerable amounts
of cytoplasmic residues like mitochondria (Mi),
heterolysosomes (Ly) and high amounts of most likely actin
filaments (Fi) (Figure 2A panel a). In contrast, MVs isolated
from the filtered supernatant did not show significant amounts
of organelles or other contaminations (Figure 2A panel b).
Thus, our data clearly show that the introduction of a filtration
step before centrifugation is important for contaminant free
MVs isolation.
Next we utilized the nanoparticle tracking analysis (ZetaView
PMX 100 system, Microtrac Europe GmbH) to determine the
size of the isolated MVs. Our data showed an average mean
diameter of 233 nm for more than 90% of all MVs isolated from
supernatants of starved HT29 cells (Figure 2B). Only 5% of the
MVs had less than 100 nm in average mean diameter and 3%
more than 800 nm following our MVs isolation protocol. These
data reflect the purity and homogeneity of our isolates seen by
electron microscopy. In general, a size range of MVs from 100
nm to 1 000 nm has been reported [4].
CEACAM-Expressing Microvesicles
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Figure 1.  Colon tumor epithelial cells release MVs in response to serum starvation.  A) Transmission electron micrographs of
HT29 cells grown under normal conditions (a) and serum starved (b) for 48 h. After culture, cells fixed, embedded in mold, cut in thin
sections and analyzed by transmission electron microscopy. B) The amount of MVs released by HT29 cells cultured in media with or
without serum was counted by flow cytometry (n=3).
doi: 10.1371/journal.pone.0074654.g001
CEACAM-Expressing Microvesicles
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Figure 2.  Introduction of a filtration step into the MVs isolation protocol significantly improves pureness of the
isolates.  A) Transmission electron micrographs of MVs isolated from serum starved HT29 supernatants by centrifugation without
(a) or with (b) prior 0.8 µm filtration step. Samples were fixed, embedded in mold, cut in thin sections and observed using
transmission electron microscopy. B) MVs filtered and isolated from serum starved HT29 cells were analyzed with the nanoparticle
tracking analysis, allowing estimating the average size distribution of MVs.
doi: 10.1371/journal.pone.0074654.g002
CEACAM-Expressing Microvesicles
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To verify the sizes of isolated MVs shown above we
performed electron microscopy of three different HT29 MVs
isolates and measured the diameters of 130 MVs. Here we
found a very heterogeneous mixture, with diameters ranging
from 90 nm to 812 nm, with an average of 320 nm ± 164 nm (n
= 130).
Epithelia, endothelia and CHO-CEACAM1 derived MVs
express distinct CEACAM expression patterns
Similar biological functions have been implicated for MVs
and members of the CEACAM family [14,34,39]. Therefore we
examined whether CEACAMs are present on MVs of epithelial
and endothelial origin. In addition, we analyzed both human
and murine endothelial cell lines to see if the assumed
CEACAM expression on MVs appears similarly in different
species. To examine if CEACAM1 positive MVs can be
generated by transfection, MVs released by CHO- and CHO-
humanCEACAM1-4L were tested for the presence of
CEACAM1. Utilizing flow cytometry, we first analyzed the
surface expression of CEACAM1 in the different cell types and
MVs derived thereof. Our results showed significant expression
of CEACAM1 in the colon tumor cell lines HT29 and T102/3,
the human endothelial cell line AS-M.5, the mouse endothelial
cell line bEnd.3 and the CHO-huCEACAM1-4L cell line with an
expression level of 64, 81, 87, 91 and 164 (median value of the
relative fluorescence), respectively (Figure 3A). MVs generated
of HT29, T102/3, AS-M.5, bEnd.3 and CHO-CEACAM1-4L
cells revealed a CEACAM1 expression level of 23, 26, 18, 25
and 21 (median value of the relative fluorescence), respectively
(Figure 3A). As expected, CHO cells and their MVs were
negative for human CEACAMs. The isotype matched control
IgG for all cell and MVs samples was set to a median value of
the relative fluorescence of 4. These results were confirmed by
CEACAM1 specific Sandwich-ELISA (data not shown).
Furthermore, we found significant expression of CD49b
(integrin alpha 2) and CD29 (integrin beta 1) on HT29 cells and
MVs released by HT29 cells (data not shown). CD49b and
CD29 are both proteins known to be present on MVs and thus
served as positive control [40]. Because it was known that
HT29 express CEACAM1, CEACAM5 and CEACAM6 we
performed Western blot analysis on lysates of HT29 cells and
HT29 derived MVs. The samples were probed with antibodies
monospecific for CEACAM1, CEACAM5 and CEACAM6. Beta
actin detection served as control for equal loading (Figure 3B).
Both HT29 cells, and MVs derived thereof, expressed
CEACAM1, CEACAM5 and CEACAM6 (Figure 3B, upper
panel). Lysates of T102/3 cells and MVs generated thereof also
stained positive for CEACAM1, CEACAM5 and CEACAM6
(data not shown). In both cases the molecular weight of the
respective CEACAM found in MVs was identical to the
molecular weight found in the parental tumor cell line. Thus,
our data show that tumor cell derived MVs carry the same
expression pattern of CEACAMs on their surface as the cell
type they were derived from. Analyses of CEACAM1 in lysates
of the human endothelial cell line AS-M.5 and their MVs
displayed the same molecular weight of the protein (Figure 3B,
lower left panel). The same was true for the murine endothelial
cell line bEND3, demonstrating that the release of CEACAM
positive MVs was not restricted to the human system (Figure
3B, lower middle panel). CHO-CEACAM1-4L and their MVs
also revealed a significant CEACAM1 expression (Figure 3B,
lower right panel). Taken together, our results clearly show the
presence of CEACAMs on MVs. Furthermore, the CEACAM
expression pattern in MVs reflected the one found on the
parental cells of which they were derived from.
Pervanadate and peroxide do not induce tyrosine
phosphorylation in MVs, but MVs induce CEACAM1
tyrosine phosphorylation in epithelial cells
Expressed in cells, CEACAM1-L can be phosphorylated on
its Tyr residues in response to various stimuli [41]. Association
of CEACAM1-L with protein-tyrosine kinases of the Src family
and the protein-tyrosine phosphatases SH2-containing Tyr
phosphatase-1 (SHP-1) and SHP-2 [19,42] were described as
initial steps of the CEACAM1 triggered signal transduction [24].
To analyze whether CEACAM1 in MVs becomes tyrosine
phosphorylated we treated isolated HT29 derived MVs with
pervanadate and H2O2, respectively. As positive control the
same treatment was performed on confluent HT29 cells.
Untreated HT29 cells and HT29 derived MVs served as
negative controls. The samples were analyzed for tyrosine
phosphorylated CEACAM1 performing an immunoprecipitation
followed by immunoblotting. As expected, in HT29 cells
tyrosine phosphorylation of CEACAM1-L was induced by
pervanadate and H2O2 treatment but not in untreated probes
(Figure 4A, left panel). In contrast, no tyrosine phosphorylation
of CEACAM1 was found in pervanadate or H2O2 treated and
untreated MVs (Figure 4A, right panel). Determining the
amount of CEACAM1 in the samples verified equal loading
(Figure 4A, lower panel). To analyze if any pervanadate and
H2O2 induced tyrosine phosphorylation appears in MVs, we
analyzed the lysates of the different samples by
immunoblotting. As shown in Figure 4B, a clear pattern of
tyrosine phosphorylation was found in lysates of un-stimulated
HT29 cells. However, the basal level of tyrosine
phosphorylation was clearly increased upon stimulation;
pervanadate triggered a stronger effect than H2O2. Although a
pattern of weak tyrosine phosphorylated proteins appeared in
HT29 derived MVs, no tyrosine phosphorylation was induced
by pervanadate and H2O2 (Figure 4B upper panel). Equal
loading was confirmed by measurement of beta-actin (Figure
4B lower panel). The results shown here were further
confirmed by analyzing AS-M.5 cells and AS-M.5 derived MVs
showing a similar outcome (data not shown). Thus, neither
CEACAM1 nor other proteins present in MVs become tyrosine
phoshorylated in response to stimulation. Of note, treatment
with both, CHO- and CHO-CEACAM1 derived MVs induces a
significant tyrosine phosphorylation in CEACAM1-L expressed
on confluent HT29 cells (Figure 5). Since the effect was much
stronger with CEACAM1-positive MVs we concluded that in
association with homophilic CEACAM1-CEACAM1 interactions,
CEACAM1 independent mechanisms can induce CEACAM1-L
tyrosine phosphorylation. Thus, CEACAM1-L itself is not
tyrosine phosphorylated in MVs but as a homophilic ligand on
MVs it augments tyrosine phosphorylation of cellular
CEACAM1-L.
CEACAM-Expressing Microvesicles
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Figure 3.  MVs released by CEACAM expressing cell types
reveal a parental cell like CEACAM expression
pattern.  Human epithelial cell (HT29, T102/3), human
endothelial cells (AS-M.5), mouse endothelial cells (bEND3),
CHO and CHO-CEACAM1 cells were serum starved for 48 h.
Subsequently culture supernatants were filtered (0.8 µm)
before MVs were isolation. Harvested cells and MVs were
analyzed by flow cytometry (A). Cells were stained for
CEACAM1 (thick line). Background fluorescence was
determined by incubating the cells with control IgG antibody
instead of anti-CEACAM1 antibody (thin line). (B) Parts of
obtained samples were lysed and then analyzed by Western
blot using anti-CEACAM1-, CEACAM5- and CEACAM6-
specific mAbs. Beta-actin detection served as control for
equally loading. The experiments shown are representative for
three independent repeats.
doi: 10.1371/journal.pone.0074654.g003
The presence of tumor derived MVs and CEACAM1-
positive MVs in anti-CD3/CD28 mAb stimulated PBMCs
leads to increased cell proliferation
To get first insights into the functional role of our highly pure
human epithelial tumor cell derived MVs we performed
proliferation tests utilizing the anti-CD3 or anti-CD3/CD28 mAb
driven PBMC stimulation approach. Treatment of freshly
isolated PBMCs with HT29 or CHO/CHO-CEACAM1 derived
MVs for three days showed no mitogenic effect in a BrdU or a
CFSE assay, respectively (Figures 6 and 7A) and did not alter
the cell survival rate (data not shown). In contrast, anti-CD3
and anti-CD3/CD28 antibody treatment induced PBMC
proliferation depending on the amount of the seeded cells
relatively strong (Figure 6) or only marginally (Figure 7A). Co-
treatment of anti-CD3 and anti-CD3/CD28 mAb with HT29 or
CHO/CHO-CEACAM1 derived MVs (Figures 6, 7A, 7B)
significantly increased induced cell proliferation. Remarkably,
the proliferation promoting impact of CHO-CEACAM1 MVs was
clearly higher than that of CHO MVs (Figure 7A). It should be
noted that PBMCs of a few donors did show a non-significant
inhibition of the CD3/CD28 triggered proliferation (data not
shown). Next, we analyzed if the T-cell co-stimulatory effect of
CEACAM1-positive, HT29 derived MVs could be prevented by
the human CEACAM1 binding mAb18/20. The presence of
mAb18/20 and the isotype-matched control IgG did not alter
the PBMC proliferation rate (not shown). Anti-CD3 antibody
alone or in combination with anti-CD28 antibodies showed low
induction of PBMC proliferation (Figure 7B, 3% and 9%,
respectively). The presence of HT29-derived MV significantly
increased the CD3 and CD3/CD28 triggered proliferation rate
to 19% and 38%, respectively (Figure 7B). This co-stimulatory
effect was reduced by mAb18/20 treatment to 10% and 23%,
respectively. In contrast, the control IgG did not change the co-
stimulatory effect of HT29-MVs (21% and 37%, respectively).
Thus, the CD3-costimulatory effect of tumor derived MVs was
at least partially inhibited by CEACAM1 binding antibodies
(Figure 7B).
Discussion
In this study we demonstrate for the first time the presence of
CEACAM family members on MVs released by epithelial and
endothelial cells of human and mouse origin. MVs are shed
from almost all cell types including tumor cells by budding off
the luminal cell membrane. They appear as spherical
extracellular nanovesicles bordered by a phospholipid
membrane. Multiple biochemicals as well as cellular stress, like
lack of nutrition and hypoxia, induce an increased release of
MVs [4]. Because MVs normally reflect the antigenic content of
the cells from which they originate, members of the CEACAM
family expressed in epithelia, endothelia, and hematopoietic
cells should be present. Since the human colon epithelial cell
line HT29 was known to express CEACAM1, CEACAM5 and
CEACAM6 we analyzed the MVs generation and the CEACAM
expression pattern in HT29 derived MVs. Here we show
electron microscopic proof that HT29 release MVs. Serum
starvation of HT29 cells triggered a massive shedding of MVs.
Similar results were found for the human colon epithelial
CEACAM-Expressing Microvesicles
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cancer cell line T102/3, as well as the human endothelial and
murine endothelial cell lines AS-M.5 and bEND3, respectively.
These findings are in accordance with recent publications
describing the constitutive and stimulation-increased release of
MVs [5]. Interestingly, blood from cancer patients also contains
elevated levels of cell-derived MVs, making our cell culture
system physiologically relevant [5]. Investigation by flow
cytometry, Western blot and ELISA revealed expression of
CEACAM1, CEACAM5 and CEACAM6 in HT29 and T102/3
derived MVs, as well as CEACAM1 expression in endothelial
Figure 4.  Pervanadate and peroxide treatment induce tyrosine phosphorylation in cells but not in corresponding
MVs.  Confluent HT29 cells and corresponding MVs were treated with pervanadate or H2O2, respectively, or left untreated. Western
blot analyzes were performed using mAb 4G10 for detecting tyrosine phosphorylation in A) the CEACAM1 immunoprecipitates, and
B) the whole cell and MVs lysates. In A) CEACAM1 detection and in B) beta-actin detection served as loading control. The data
show one representative result of three independent repeats of the experiment.
doi: 10.1371/journal.pone.0074654.g004
CEACAM-Expressing Microvesicles
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cell derived MVs. Although evidence for the presence of
CEACAM5 in tumor derived MVs has been previously reported,
no thorough analysis on CEACAMs in MVs has been published
[43]. The CEACAM expression in MVs was not restricted to
humans but was also found in mice. Accordingly, the CEACAM
expression profile in MVs reflected the expression pattern of
the cell type they were derived from.
Our studies were performed on MVs isolated from 0.8 µm
filtered cell supernatants centrifuged for 1 hour at 41 000 g and
4°C. In the beginning we followed standard isolation protocols
found in the literature utilizing centrifugation conditions from
18 000 g to 100 000 g for one hour [38]. Unfortunately, MVs
isolated following such protocols resulted in isolates containing
many contaminants e.g. with mitochondria and
heterolysosomes. Introducing a 0.8 µm filtration step into our
MVs isolation procedure greatly improved the purity of the
isolates allowing us to produce MVs populations with barely
any contamination. The size determinations utilizing the novel
Microtrac ZetaView PMX 100 system showed that over 90% of
the isolated MVs had an average diameter of 233 nm.
Therefore we concluded that HT29 derived MVs were fairly
homogeneous in size. Although the electron microscopic MVs
size determination resulted in an average diameter of 320 nm,
a value, which was near the one measured with the Microtrac
ZetaView PMX 100 system, the range distribution of the size
was broadly scattered and reached from 90 to 800 nm.
Previous studies also revealed that MVs shed from tumor cells
appear to be rather heterogeneous in their sizes [4]. However,
the procedure for generating the material for electron
microscopy may be the reason for the significant change from
the raw material to isolated MVs. Because the Microtrac
ZetaView PMX 100 measures the MVs sizes from supernatants
or MVs isolates without prior processing it appeared to be the
superior system for size measurements of small nanoparticles.
Having established a reliable method for the isolation of pure
tumor cell derived MVs we addressed the question of their
functional impact. First we analyzed if CEACAM1 is able to
transduce signals into the MVs as it has been shown to do so
in various cell types [14]. Tyrosine-phosphorylation of the
cytomplasmic tail of CEACAM1-L was described to be the
initial step of the signaling processes. Our results revealed that
CEACAM1 present on MVs did not become tyrosine
phosphorylated despite treatment with strong stimuli such as
peroxide and the plasma membrane permeable constitutive
phosphatase inhibitor pervanadate. Interestingly, we could not
induce tyrosine phosphorylation of any of the proteins present
in the MVs by our treatments. We concluded that the molecular
machinery necessary for signaling via tyrosine phosphorylation
is either not functioning or absent in MVs. Therefore we
postulate that CEACAM1 and other CEACAMs present on MVs
function solely as ligand. Our finding that CEACAM1 positive
MVs induced strong tyrosine phosphorylation of CEACAM1 in
epithelial cells supported this hypothesis. To a lesser extent,
also CEACAM1 negative MVs triggered CEACAM1
phosphorylation in epithelial cells. Although the signaling
machinery regulating this tyrosine phosphorylation needs to be
discovered, it clearly shows the co-stimulatory potential of
CEACAM1. Thus CEACAMs on MVs mediate the homophilic/
Figure 5.  CHO- and CHO-CEACAM1 derived MVs induce the CEACAM1-L tyrosine phosphorylation in confluent HT29
cells.  CEACAM1 immunoprecipitates of confluent HT29 cells treated for 15 min with CHO- and CHO-CEACAM1 derived MVs were
probed for tyrosine phosphorylation (upper panel) and CEACAM1 (lower panel) as control for equal loading. Untreated cells were
used as negative control. Pervanadate was used to induce CEACAM1-L tyrosine phosphorylation. The data show one
representative result of three independent repeats of the experiment.
doi: 10.1371/journal.pone.0074654.g005
CEACAM-Expressing Microvesicles
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heterophilic interaction with transmembrane anchored
CEACAM1 expressed on various cell types, consequently
inducing signal transduction and cellular processes.
Baring in mind that MVs interact specifically with cells they
recognize via binding to specific, membrane-bound receptors
and that both MVs and CEACAMs can be involved in tumor
immune suppression we focused on analyzing the putative
MVs effect on T-lymphocyte stimulation. We combined the
well-established anti-CD3 and anti-CD3/CD28 mAb triggered
T-cell stimulation with isolated tumor cell line-derived
CEACAM-positive MVs or CHO/CHO-CEACAM1 derived MVs.
Our results show a significant increase of T-cell proliferation.
Thus, CEACAM1 positive MVs showed a stronger effect than
CEACAM1-negative ones and the CEACAM1 binding
mAb18/20 significantly decreased the co-stimulatory effect of
CEACAM1 bearing MVs. At first this result was unexpected
because previous reports described the release of
immunosuppressive MVs/exosomes by tumor cells [13]. This
has been supported by studies showing expression of FasL,
TRAIL and TGF- Beta on tumor derived-exosomes [44]. In that
context one should note that most of the previous studies
focused on exosomes and not on MVs. Moreover, a negative
effect on T-cell stimulation would have been in line with reports
stating that CEACAM1 is also an inhibitor of T-cell proliferation
[14]. However, more recent reports showed that tumor derived
MVs are able to increase stimulated T-cell proliferation [45] and
also CEACAM1 can act as intensifying co-receptor of the T-cell
receptor [22]. It is likely that the complex composition of
different components is responsible for the different functional
outcomes in the respective cell types. Further studies analyzing
the proteome as well as the RNA load might give a better
insight into the functional potential of different MVs. However,
because MVs interact specifically with cells they recognize by
binding to specific receptors, the CEACAM expression on MVs
is clearly a mechanism of interaction between MVs and
CEACAM expressing cell types.
The release of CEACAM positive MVs from tumor cells could
also be a mechanism by which cells lower the amount of these
surface proteins. It is well documented that malignant
degeneration of epithelial cells lead to a decreased expression
of CEACAM1 [35] and perhaps budding off in MVs is the
mechanism of this finding. Tumor cell released MVs may also
explain the increased levels of different CEACAMs in serum,
plasma and urine of patients suffering tumors and other
diseases. Therefore it might be of diagnostic interest to
distinguish whether CEACAMs are present in a non-membrane
bound soluble form or as protein anchored to the membrane of
MVs and exosomes in the different body fluids.
Figure 6.  Tumor cell derived MVs promote the proliferative impact of anti-CD3/CD28 mAb stimulation on PBMC.  Freshly
isolated human PBMC were kept for 3 days in the presence of CD3/CD28, CD3/CD28/MVs and MVs alone. As control untreated
cells were used. For the last 14-18 h of cell culture the BrdU compound (Roche) was added. Then the cell proliferation assay was
performed according to the manufacturer’s protocol. Experiments were performed in triplicates and results presented are expressed
as means of OD 450 nm ± SD. The data show one representative result of four independent repeats of the experiment. The
difference between the control group and the CD3/CD28 and CD3/CD28/MVs treated groups as well as the CD3/CD28 and CD3/
CD28/MVs treated groups were determined by student t-test (*p≤0.005 and **p≤0.0065, respectively; n=3).
doi: 10.1371/journal.pone.0074654.g006
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Figure 7.  CEACAM1-positive MVs significantly increase the anti-CD3 and anti-CD3/CD28 mAb triggered T-cell
proliferation.  Freshly isolated human PBMC were labeled with CFSE and cultured for 4 days in the presence of anti CD3 and anti
CD3/CD28 with and without CHO- and CHO-CEACAM1 derived MVs (A). B) CFSE labeled PBMC were cultured for 4 days in the
presence and absence of antiCD3 and antiCD3/CD28 with and without HT29-derived MVs. Untreated treated cells served as
control. In indicated cases samples were co-cultured with antiCEACAM1 mAb18/20 (50 µg/ml) or isotype matched control IgG (50
µg/ml). Then PBMCs were analyzed utilizing the Accuri C6 flow cytometer system. The histograms depict PBMCs that have divided
1-3 times based on CFSE dilution peaks and reflex the cell proliferation rate given in %. The data shown are representative for three
independent repeats of the experiment.
doi: 10.1371/journal.pone.0074654.g007
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Materials and Methods
Cell culture and antibodies
The human colon cancer cell line HT29 was obtained from
DSMZ Braunschweig, Germany. The human colon cancer cell
line T102/3 was kindly provided by R. Kammerer (FLI,
Greifswald, Germany) [46]. The murine cell line (bEnd.3)
derived from mouse cortex endothelium was purchased from
ATCC (USA). The CHO-huCEACAM1 cell line was generated
by stable transfection of CHO-cells with the pcDNA3.1-human
CEACAM1-4L vector, subsequent G418 selection and
subcloning. HT29, T102/3, CHO, CHO-CEACAM1 and bEnd3
were maintained in Dulbecco’s modified Eagle’s medium
(Gibco) supplemented with 10% (v/v) heat-inactivated FCS
(PAA), 2 mM L-glutamine (Gibco), 100 µg/ml penicillin (Gibco),
and 100 µg/ml streptomycin (Gibco) in a humidified 5% CO2 at
37°C atmosphere. The human microvascular endothelia cell
line AS-M.5 [47] was cultured in ECG medium (PromoCell).
The different mAbs specific for CEACAM1 (B3-17, C5-1X),
CEACAM5 (5C8C4), CEACAM6 (1H7-4B) and CEACAM1/3/5
(18/20) were generated by B.B. Singer (Anatomy, University
Hospital Essen, Germany). The mouse mAb anti mouse
CEACAM1 was kindly provided by K. Holmes (University of
Colorado, USA). The phospho-tyrosine mAb 4G10 was
purchased from MerckMillipore (Schwalbach, Germany), the
CD29 (clone MEM101-A), CD49b (clone 10-G11) CD3 (clone
UCHT-1) and CD28 (clone 15E8) were from Immunotools
(Friesoythe, Germany).
Isolation of MVs
The different adherent growing epithelial, endothelial, CHO
and CHO-CEACAM1 cell lines were cultured in 20 ml medium
until they reached tight confluence. Then the cells were
washed twice with PBS and cultured under starving condition in
DMEM medium lacking FCS to provoke stress related release
of MVs. The cell culture supernatants were collected after 72
hours and centrifuged at 1 500 g for 20 minutes to remove cells
and bigger cells debris. Thereafter supernatants were filtered
through a 0.8 µm filter (Pall Life Sciences, Dreieich, Germany)
to remove larger cell organelles, vesicles and apoptotic
fragments and centrifuged at 41 000 g for 1 hour at 4°C. The
supernatant was discarded and the MVs in the pellets were
resuspended in 30 ml PBS and centrifuged at 41 000 g for 1
hour at 4°C. The MVs pellets were resuspended in 100 µl 4°C
PBS and stored at 4°C until further use. The protein
concentration of the MVs isolates was determined by the Lowry
protein assay (Bio-Rad, Munich, Germany) according to
manufacturer’s instructions.
Nano particle tracking analysis (NTA)
NTA was performed by using the ZetaView (Particle Metrix,
Meerbusch, Germany). The instrument tracks the Brownian
motion of laser beam illuminated particles over time and
subsequently calculate particle sizes and concentrations.
Comparable to exosome-enriched fractions, 1:500 or 1:1000
H2O diluted MV probes were measured in duplicates [48].
Electron microscopy
Cells were cultured on Thermanox® wafers for 3 days in
DMEM medium with and without FCS. Medium was withdrawn
by careful suction and replaced by 2 ml of a solution of 2.5%
glutaraldehyde in 0.1 Mol cacodylate buffer (pH 7.4; room
temperature). This was followed 90 min. later by washing in
cacodylate buffer (3x 20 min). Osmification with 1%
osmiumtetroxide in cacodylate buffer for 60 min was followed
by washing in cacodylate buffer (3x 20 min). Then aqueous
ethanol solutions were applied (30% -45 min, 50% -45 min.)
and 70%. The latter solution also contained 1% of uranyl
acetate and was incubated for 60 min. After this 80%, 90%,
and 96% ethanol (45 min each) and pure ethanol were applied
(3x 10 min each) followed by EPON® solutions in ethanol with
increasing EPON® concentration (ethanol: EPON® = 3:1, 1:1,
1:3; 60 min each) and finally pure EPON® overnight at room
temperature. Embedding was performed in flat embedding
molds whereby Thermanox® wafers were put upside-down on
the molds avoiding air bubbles. A heated storage (60°C, 2
days) was used for polymerization. Then Thermanox® wafers
were removed using a crimper on a heating plate at 90°C and
peeled off from the underlaying Epon. After trimming solid
EPON® blocs were cut on a Reichert-Jung Ultracut®
ultramicrotome set to a thickness of 60 nm. Sections were then
mounted on 200 Mesh hexagonal copper grids and treated with
1% uranyl acetate solution for 4 min. In several, but not all
cases this was followed by 3 min of lead citrate (0.4%) for
contrast enhancement. A Zeiss transmission electron
microscope (EM 902A) was used for final investigation at 80
KV at magnifications from 3 000 to 140 000 x. Digital image
acquisition was performed by a MegaViewII slow-scan-CCD
camera connected to a PC running ITEM ®5.0 software (Soft-
imaging-systems, Münster, Germany). Images were stored as
uncompressed TIFF files in 16 bits of gray and further
processed using Adobe®Photoshop®CS5.
Western blotting
A fraction of the harvested cells and their corresponding MVs
were lysed on ice for 30 min in RIPA based lysis buffer [50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate) supplemented with protease inhibitor cocktail set
III (Calbiochem) and PhosSTOP phosphatase inhibitor cocktail
(Roche). Lysates were centrifuged at 10 000 g at 4°C for 15
min and 50 µg of total protein was subjected to Tricine-PAGE,
blotted to nitrocellulose membrane (Applichem, Germany) and
reacted with respective primary anti-CEACAM1, anti-
CEACAM5, anti-CEACAM6 and anti P-Tyr antibody followed by
HRP-coupled secondary goat anti mouse antibody (Dianova,
Germany). Anti-β-actin antibody was used to confirm equal
loading. Then Western blots were reacted with luminol solution
and the chemiluminescence reaction was visualized by the
LAS3000 Image analyzer (Fuji, Japan).
Immunoprecipitation
A fraction of the indicated cells, their corresponding MVs and
HT29 cells cultured for 15 min with and without 50 µM
pervanadate (Pierce, Germany) as well as CHO- and CHO-
CEACAM1 derived MVs were lysed in RIPA based lysis buffer
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supplemented with protease inhibitor cocktail set III
(Calbiochem) and PhosSTOP phosphatase inhibitor cocktail
(Roche). Cell and MVs lysates were centrifuged at 10 000 g at
4°C for 15 min. For preclearance, samples were incubated for
1 hour at 4°C with 30 µl protein G sepharose 4 Fast Flow
beads (GE Healthcare, USA). Then, the samples were
centrifuged for 1 minute at 800 g and the supernatant
transferred into fresh tubes. 5 µg of the CEACAM1 binding
mAb 18/20 was added to the lysates and incubated for 2 hours
at 4°C under permanent rotation followed by incubation with 30
µl protein G sepharose at 4°C overnight. The antigen–antibody-
protein G bead complexes were pelleted by centrifugation at
400 g for 30 sec and washed three times with PBS. Thereafter,
60 µl Laemli buffer containing 75 mM β-mercaptoethanol was
added to the dry pellet and samples were boiled at 98°C for 10
min. Subsequently, the samples were centrifuged at 2300 g for
1 min and equal volumes of the probes were applied to Tricine-
PAGE and transferred onto nitrocellulose membrane as
described above.
Flow cytometry
Cells (5×105) and MVs were stained with mAbs (20 µg/ml)
anti-human CEACAM1 (B3-17) and anti-mouse CEACAM1
(CC1) diluted in 3% FCS/PBS for 1 h on ice, washed with ice-
cold PBS, and incubated with FITC conjugated anti-mouse
F(ab')2 (Dianova, Germany). Background fluorescence was
determined using isotype-matched Ig mAb. The stained cell
samples were examined in a FACScalibur flow cytometer (BD
Biosciences, San Diego, CA) and the data were analyzed
utilizing the CellQuest software. Where applicable, dead cells,
identified by PI staining, were excluded from the determination.
In some cases the content of unstained MVs present in the
different cell culture supernatants was determined by
measuring the samples for one minute (counts per minute).
Tyrosine phosphorylation
A fraction of confluent HT29 cells and corresponding MVs
were treated for 15 min. at 37°C with 50 µM freshly prepared
pervanadate (Pierce, Germany). Another fraction was
incubated with 0.03% H2O2 or left untreated. In addition,
confluent HT29 cells were treated with CHO or CHO-
CEACAM1 derived MVs, respectively. Thereafter samples
were immediately harvested by centrifugation and lysed in
RIPA buffer supplemented with protease inhibitor cocktail set III
(Calbiochem) and PhosSTOP phosphatase inhibitor cocktail
(Roche) for 30 min on ice. The insoluble material was removed
by centrifugation at 18 620 g at 4°C for 10 minutes.
Subsequently the lysates were either used for the CEACAM1
immunoprecipitation or directly applied for Western blot
analyzes.
Peripheral blood mononuclear cells (PBMC) isolation
Heparinized venous blood was obtained from healthy
volunteers in accordance with a protocol approved by the
Ethical Review Committee of the University Duisburg-Essen.
The participants provided their written informed consent to
participate in this study. PBMC were isolated using Ficoll-
Hypaque density-gradient centrifugation followed by hypotonic
lysis of contaminating erythrocytes if required. The purity of the
isolated PBMCs were 90–96% as determined with the
FACSCalibur flow cytometer utilizing the CellQuest software
(BD Biosciences) with a viability of >97% as measured by
trypan blue exclusion. PBMC were resuspended in RPMI
(GIBCO) supplemented with 10% (v/v) heat inactivated fetal
calf serum (FCS) and 2 mM L-glutamine, 100 IU/ml penicillin,
100 mg/ml streptomycin, and kept on ice until further use.
PBMC proliferation assays
The proliferation effect of MVs was studied using a BrdU
Proliferation Kit (Roche) according to the manufacturers’
protocol. Briefly, 160 000 monocyte-depleted PBMCs/well of a
96 well flat bottom plate were cultured for 3 days with 0.5 µg/ml
anti-CD3 and 1 µg/ml anti CD28 in the presence or absence of
MVs as described in the figure legends. PBMCs alone or only
with MVs served as controls. During the last 18 h BrdU reagent
was added into the wells. Then PBMCs were pelleted down,
fixed, washed, blocked and incubated with HRP-coupled BrdU
detecting antibody. Finally, cells were washed and developed
with TMB Xtra-substrate (Kementec Diagnostics). The reaction
was stopped with 1 M H2SO4 and the OD was measured in a
Sunrise-ELISA reader (Tecan, Crailsheim, Germany). All
measurements were determined in triplicates.
The CFSE approach (CellTrace™ CFSE Cell Proliferation
Kit, Molecular Probes™, USA) served as further method for the
analysis of cell proliferation. Therefore freshly isolated PBMCs
(106 cells/ml) were incubated with 2 µM CFSE for 15 min at
37°C. The cell labeling was quenched by adding five volumes
of ice-cold RPMI (10% FCS) for 5 min. Then the cells were
washed twice in ice-cold RPMI 1640 (Gibco). According to
previous pilot experiments revealing the cell culture condition in
which PBMC barely react to CD3 and CD3/CD28 stimulation,
100.000 cells/2.2 ml were cultured in the presence or absence
of anti CD3 (0.5 µg/ml, clone UCHT-1) and anti CD3 plus CD28
(1 µg/ml CD28) with or without MV isolated from indicated cell
types in 24-well plates (Nunc, Denmark) at 37°C, humid
atmosphere, 5% CO2 in RPMI supplemented with antibiotics
and 10% autologous plasma. In some cases CEACAM1
binding mAb18/20 (50 µg/ml) or isotype matched control IgG
(50 µg/ml) was applied to the samples. Untreated PBMCs
served as negative control for cell reactivity. After 4 days of
cultivation, the cells were collected and analyzed utilizing the
Accuri C6 system (Becton Dickinson), 50.000 events per
sample were acquired and the viable lymphocytes were
selected according to their forward (FSC) and side scatter
(SSC) characteristics. Then, the CFSE fluorescence profile of
the PBMCs was displayed as histogram and the fraction of
proliferating PBMCs was determined.
Statistical Analysis
Where applicable, data are presented as the mean ± SD.
Statistical significance was determined utilizing the Student’s t-
test. Differences were considered statistically significant at a P
value of <0.05.
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